4D Pharma has identified a bacteria for the potential treatment of multiple sclerosis
4D Pharma (AIM DDDD) is a pharmaceutical company which operates in the field of biotherapeutics – products derived from DNA technology which provide a major advance in the safety and effectiveness of treatments for a variety of serious illnesses. The Group, which listed on AIM in early 2014, aims to discover and develop new live biotherapeutics. It has developed a proprietary platform, the MicroRx for the discovery of novel biotherapeutics and has today issued a positive research update on this exciting tool.
The Group, using the MicroRx, has identified bacteria that has the potential to treat multiple sclerosis. This bacteria has undergone pre-clinical trials (conducted by an external source) and the results indicate there is huge potential for the use of this bacteria in prevention of the development of the disease. The results are an exciting development in the progression of live biotherapeutics as they offer an opportunity to potentially treat multiple sclerosis with an oral capsule…
Previous article Next article
